Charlotte Sværke Jørgensen

Charlotte Sværke Jørgensen

Auto-generated profile, based on publicly available information

Charlotte Sværke Jørgensen

Department of Virus and Microbiological Preparedness Statens Serum Institut Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RLRia Lassaunière
Ria Lassaunière
AFAnders Frische
Anders Frische
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
ANAlex Christian Yde Nielsen Nielsen
Alex Christian Yde Nielsen Nielsen
AFAnders Fomsgaard
Anders Fomsgaard
CJCharlotte S. Jørgensen
Charlotte S. Jørgensen
Due to urgency and demand, numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoassays are rapidly being developed and placed on the market with limited validation on clinical samples. Thorough validation of serological tests are required to facilitate their use in the accurate diagnosis of SARS-CoV-2 infection, confirmation of molecular results, contact tracing, and epidemiological studies. This study evaluated the sensitivity and specificity of nine commercially available serological tests. These included three enzyme-linked immunosorbent assays (ELISAs) and six point-of-care (POC) lateral flow tests. The assays were validated using serum samples from: i) SARS-CoV-2 PCR-positive patients with a documented first day of disease; ii) archived sera obtained from healthy individuals before the emergence of SARS-CoV-2 in China; iii) sera from patients with acute viral respiratory tract infections caused by other coronaviruses or non-coronaviruses; and iv) sera from patients positive for dengue virus, cytomegalovirus and Epstein Barr virus. The results showed 100% specificity for the Wantai SARS-CoV-2 Total Antibody ELISA, 93% for the Euroimmun IgA ELISA, and 96% for the Euroimmun IgG ELISA with sensitivities of 90%, 90%, and 65%, respectively. The overall performance of the POC tests according to manufacturer were in the rank order of AutoBio Diagnostics > Dynamiker Biotechnology = CTK Biotech > Artron Laboratories > Acro Biotech ≥ Hangzhou Alltest Biotech. Overall, these findings will facilitate selection of serological assays for the detection SARS-CoV-2-specific antibodies towards diagnosis as well as sero-epidemiological and vaccine development studies.

12 January 2021 in Animals
Verified
Journal Article
Open access
PDF file
ABAnette Boklund
Anette Boklund
AHAnne Sofie Vedsted Hammer
Anne Sofie Vedsted Hammer
MQMichelle Lauge Quaade
Michelle Lauge Quaade
TRThomas Bruun Rasmussen
Thomas Bruun Rasmussen
LLLouise Lohse
Louise Lohse
ABAnette Bøtner
Anette Bøtner
SARS-CoV-2 infection is the cause of COVID-19 in humans. In April 2020, SARS-CoV-2 infection in farmed mink (Neovision vision) occurred in the Netherlands. The first outbreaks in Denmark were detected in June 2020 in three farms. A steep increase in the number of infected farms occurred from September and onwards. Here, we describe prevalence data collected from 215 infected mink farms to characterize spread and impact of disease in infected farms. In one third of the farms, no clinical signs were observed. In farms with clinical signs, decreased feed intake, increased mortality and respiratory symptoms were most frequently observed, during a limited time period (median of 11 days). In 65% and 69% of farms, virus and sero-conversion, respectively, were detected in 100% of sampled animals at the first sampling. SARS-CoV-2 was detected, at low levels, in air samples collected close to the mink, on mink fur, on flies, on the foot of a seagull, and in gutter water, but not in feed. Some dogs and cats from infected farms tested positive for the virus. Chickens, rabbits, and horses sampled on a few farms, and wildlife sampled in the vicinity of the infected farms did not test positive for SARS-CoV-2. Thus, mink are highly susceptible to infection by SARS-CoV-2, but routes of transmission between farms, other than by direct human contact, are unclear.

1 January 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CHCecilie Bo Hansen
Cecilie Bo Hansen
IJIda Jarlhelt
Ida Jarlhelt
LPLaura Pérez-Alós
Laura Pérez-Alós
LLLone Hummelshøj Landsy
Lone Hummelshøj Landsy
MLMette Loftager
Mette Loftager
MSMikkel-Ole Skjoedt
Mikkel-Ole Skjoedt
Globally, the COVID-19 pandemic has had extreme consequences for the healthcare system and has led to calls for diagnostic tools to monitor and understand the transmission, pathogenesis, and epidemiology, as well as to evaluate future vaccination strategies. In this study, we have developed novel, to our knowledge, flexible ELISA-based assays for specific detection of human SARS-CoV-2 Abs against the receptor-binding domain, including an Ag sandwich ELISA relevant for large population screening and three isotype-specific assays for in-depth diagnostics. Their performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infection, ranging from asymptomatic to critical cases. We mapped the Ab responses to different areas on protein N and S and showed that the IgM, A, and G Ab responses against receptor-binding domain are significantly correlated to the disease severity. These assays and the data generated from them are highly relevant for diagnostics and prognostics and contribute to the understanding of long-term COVID-19 immunity.

1 September 2015 in Journal of Microbiological Methods
Verified
Journal Article
Closed access
CJCharlotte S. Jørgensen
Charlotte S. Jørgensen
SUSøren Anker Uldum
Søren Anker Uldum
JSJesper F. Sørensen
Jesper F. Sørensen
ISIan C. Skovsted
Ian C. Skovsted
SOSanne Otte
Sanne Otte
PEPernille L. Elverdal
Pernille L. Elverdal

1 April 2004 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
CJC. S. Jørgensen
C. S. Jørgensen
MCM. Christiansen
M. Christiansen
BNB. Nørgaard‐Pedersen
B. Nørgaard‐Pedersen
EØE. Østergaard
E. Østergaard
FSF. V. Schiødt
F. V. Schiødt
GHGunnar Houen
Gunnar Houen
Gc globulin, also called vitamin D‐binding protein, is a plasma protein involved in the actin‐scavenger system. In this study, the total Gc globulin concentration in serum or plasma samples was determined using a new, fast, solid‐phase inhibition assay. Included in the study were 228 healthy volunteers (131 M, 97 F), 22 pregnant women, 90 cancer patients and 9 patients with chronic liver disease. Moreover, the degree of complexing with actin was determined in selected samples using crossed immunoelectrophoresis. The Gc globulin level in healthy controls was in the range 176–623 mg/L, showing no age dependency. The median level was found to be significantly higher in women than in men. Gc globulin concentrations were raised during pregnancy, showing a median value of 541 mg/L in the first trimester, and slightly raised to 574 mg/L in the second trimester. Cancer patients showed no changes in Gc globulin level, and there was no sign of increased amounts of complexing with actin. Chronic liver patients showed increased levels of Gc globulin following transplantation, but no signs of complexing with actin. This new solid‐phase inhibition assay is fast, it is a good complement to the existing quantification methods, and it is especially suitable for determination of the Gc globulin status in acute liver patients before and during treatment.

15 November 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
TRThomas Bruun Rasmussen
Thomas Bruun Rasmussen
JFJannik Fonager
Jannik Fonager
CJCharlotte Sværke Jørgensen
Charlotte Sværke Jørgensen
RLRia Lassaunière
Ria Lassaunière
AHAnne Sofie Hammer
Anne Sofie Hammer
ABAnette Bøtner
Anette Bøtner
Mink, on a farm with about 15,000 animals, became infected with SARS-CoV-2. Over 75% of tested animals were positive for SARS-CoV-2 RNA in throat swabs and 100% of tested animals were seropositive. The virus responsible had a deletion of nucleotides encoding residues H69 and V70 within the spike protein gene as well as the A22920T mutation, resulting in the Y453F substitution within this protein, seen previously in mink. The infected mink recovered and after free-testing of 300 mink (a level giving 93% confidence of detecting a 1% prevalence), the animals remained seropositive. During further follow-up studies, after a period of more than 2 months without any virus detection, over 75% of tested animals again scored positive for SARS-CoV-2 RNA. Whole genome sequencing showed that the viruses circulating during this re-infection were most closely related to those identified in the first outbreak on this farm but additional sequence changes had occurred. Animals had much higher levels of anti-SARS-CoV-2 antibodies in serum samples after the second round of infection than at free-testing or during recovery from initial infection, consistent with a boosted immune response. Thus, it was concluded that following recovery from an initial infection, seropositive mink were readily re-infected by SARS-CoV-2.